Floatz logo

Rivoceranib

Metastatic Castration-resistant Prostate Cancer (CRPC)

Pengyuan LiuSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Metastatic Castration-resistant Prostate Cancer (CRPC) cohort.

Asset / SponsorPhaseRating
-9bms
TechnoGenesys, Inc.
Phase 1CC

Same molecule, other indications

Rivoceranib is also rated in:

gastric cancerDormant
BBB
Indicative ·
73 / 100
View asset →
peripheral T-cell lymphoma, not otherwise specifiedDormant
BBB
Indicative ·
72 / 100
View asset →
ApatinibDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →